Ironwood Pharmaceuticals Inc (IRWD) stock
IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3063% below fair value
$4.87+0.02 (+0.41%)
Close on Nov 17, 2026Market cap $804.72MP/E 6.3Yield –
Ironwood Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Ironwood Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $389.32M, up 26.2% year over year. For fiscal 2025 it was $296.15M, down 15.7% from the year before. Over ten years it grew 7.1% a year on average. The highest annual figure on record is $442.74M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $296.15M | -15.7% |
| FY2024 | Dec 31, 2024 | $351.41M | -20.6% |
| FY2023 | Dec 31, 2023 | $442.74M | +7.8% |
| FY2022 | Dec 31, 2022 | $410.60M | -0.8% |
| FY2021 | Dec 31, 2021 | $413.75M | +6.2% |
| FY2020 | Dec 31, 2020 | $389.52M | -9.1% |
| FY2019 | Dec 31, 2019 | $428.41M | +23.6% |
| FY2018 | Dec 31, 2018 | $346.64M | +16.2% |
| FY2017 | Dec 31, 2017 | $298.28M | +8.9% |
| FY2016 | Dec 31, 2016 | $273.96M | +83.2% |
| FY2015 | Dec 31, 2015 | $149.56M | +95.7% |
| FY2014 | Dec 31, 2014 | $76.44M | +234.1% |
| FY2013 | Dec 31, 2013 | $22.88M | -84.8% |
| FY2012 | Dec 31, 2012 | $150.25M | +128.1% |
| FY2011 | Dec 31, 2011 | $65.87M | +50.2% |
| FY2010 | Dec 31, 2010 | $43.86M | +27.8% |
| FY2009 | Dec 31, 2009 | $34.32M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $113.04M | +32.6% |
| Q1 FY2026 | Mar 31, 2026 | $106.51M | +158.9% |
| Q4 FY2025 | Dec 31, 2025 | $47.71M | -47.3% |
| Q3 FY2025 | Sep 30, 2025 | $122.06M | +33.3% |
| Q2 FY2025 | Jun 30, 2025 | $85.24M | -9.7% |
| Q1 FY2025 | Mar 31, 2025 | $41.14M | -45.1% |
| Q4 FY2024 | Dec 31, 2024 | $90.55M | -23.0% |
| Q3 FY2024 | Sep 30, 2024 | $91.59M | -19.5% |
| Q2 FY2024 | Jun 30, 2024 | $94.40M | -12.1% |
| Q1 FY2024 | Mar 31, 2024 | $74.88M | -28.0% |
| Q4 FY2023 | Dec 31, 2023 | $117.55M | +9.7% |
| Q3 FY2023 | Sep 30, 2023 | $113.74M | +4.7% |
| Q2 FY2023 | Jun 30, 2023 | $107.38M | +10.4% |
| Q1 FY2023 | Mar 31, 2023 | $104.06M | +6.7% |
| Q4 FY2022 | Dec 31, 2022 | $107.20M | -8.5% |
| Q3 FY2022 | Sep 30, 2022 | $108.64M | +4.7% |
| Q2 FY2022 | Jun 30, 2022 | $97.23M | -6.5% |
| Q1 FY2022 | Mar 31, 2022 | $97.53M | +9.8% |
| Q4 FY2021 | Dec 31, 2021 | $117.13M | +0.4% |
| Q3 FY2021 | Sep 30, 2021 | $103.75M | +0.3% |
| Q2 FY2021 | Jun 30, 2021 | $104.03M | +16.3% |
| Q1 FY2021 | Mar 31, 2021 | $88.85M | +11.1% |
| Q4 FY2020 | Dec 31, 2020 | $116.68M | -7.6% |
| Q3 FY2020 | Sep 30, 2020 | $103.47M | -21.1% |
| Q2 FY2020 | Jun 30, 2020 | $89.43M | -12.5% |
| Q1 FY2020 | Mar 31, 2020 | $79.94M | +16.3% |
| Q4 FY2019 | Dec 31, 2019 | $126.30M | -3.4% |
| Q3 FY2019 | Sep 30, 2019 | $131.17M | +99.7% |
| Q2 FY2019 | Jun 30, 2019 | $102.22M | +26.0% |
| Q1 FY2019 | Mar 31, 2019 | $68.73M | -0.6% |
| Q4 FY2018 | Dec 31, 2018 | $130.69M | +38.7% |
| Q3 FY2018 | Sep 30, 2018 | $65.69M | -24.3% |
| Q2 FY2018 | Jun 30, 2018 | $81.11M | +24.6% |
| Q1 FY2018 | Mar 31, 2018 | $69.16M | +32.6% |
| Q4 FY2017 | Dec 31, 2017 | $94.21M | +7.7% |
| Q3 FY2017 | Sep 30, 2017 | $86.83M | +31.3% |
| Q2 FY2017 | Jun 30, 2017 | $65.08M | – |
| Q1 FY2017 | Mar 31, 2017 | $52.17M | – |
| Q4 FY2016 | Dec 31, 2016 | $87.46M | – |
| Q3 FY2016 | Sep 30, 2016 | $66.11M | – |
See a number that looks wrong?